Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Study Overview

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of a novel Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody (AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors. This study will also determine the RP2D of AGEN1181 monotherapy.

Study Description

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti?CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

  • ClinicalTrials.gov Identifier: NCT03860272
  • Protocol Number: 19-132
  • Principal Investigator: Andrea Bullock
  • Principal Investigator: Central PIO

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000